Ex vivo engineering of hematopoietic stem cells using RNA-LNPs for cell and gene therapies
Sponsor
Delivering nucleic acids using lipid nanoparticles (LNP) to target cells has tremendous potential to enable new cell and gene therapies. In this webinar, we'll share insights on an innovative genomic medicines toolkit, focusing on technologies that streamline the development of RNA-LNP medicines.
We're excited to introduce you to off-the-shelf reagents designed specifically for producing RNA-LNPs optimized for hematopoietic stem cells (HSC), alongside the NanoAssemblr™ manufacturing platform equipped with NxGen™ technology. This platform can enable rapid development and scale-up production of RNA-LNPs. Through this presentation, we will walk you through data for ex vivo hematopoietic stem cell therapies showcasing how LNPs serve as a vehicle for RNA delivery for the transient expression of therapeutic genes and gene-editing nucleases.
Join us in this webinar to learn more about:
- How RNA-LNPs are being used to develop the next-generation of HSC therapies
- How to perform highly efficient gene editing in CD34+ HSCs
- Seamless integration of LNPs in CD34+ HSC cell manufacturing workflow
- Scaling up ex vivo cell therapy from discovery to preclinical using the NanoAssemblr™ LNP manufacturing platform
SPEAKERS
You might also like
Developing off-the-shelf CAR-NK cells targeting CD70: updates from preclinical and early clinical studies
Characterization and release testing for AAV therapies: empty/partial/full capsid analysis and impact on potency
Development of a non-viral gene delivery platform for CAR-T manufacturing
Supporting efficacy and scaling with a next-generation T cell AOF formulation medium
